Clinical trials: Six Minute Walk Test
Pulmonary Hypertension, Interstitial Lung Disease
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02630316
- Testing
- Inhaled Treprostinil
- Where
- 97 sites in United States, Puerto Rico
- Volunteers
- 326 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
- Trial name
- TRUST-2 (NCT03055221)
- Testing
- Intravenous Treprostinil
- Volunteers
- 20 people
- Sponsor
- United Therapeutics
COPD
Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Determine the affect of the Portable Oxygen Concentrator (POC) on improvements in: 1.
- Trial name
- NCT01948544
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- StratiHealth
Lymphangioleiomyomatosis
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
- Trial name
- NCT01059318
- Testing
- Everolimus
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
- Trial name
- FREEDOM-EV (NCT01560624)
- Testing
- Treprostinil Diolamine
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 690 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
This is a multicenter, single-arm trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03012646
- Testing
- Inhaled Treprostinil
- Sponsor
- United Therapeutics
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Patient Centered Outcomes Analysis for MS Using a Mobile Application
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that can impact all aspects of nervous system function.
- Trial name
- NCT04281160
- Testing
- BeCare Mobile App
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeCare Link LLC
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure…
- Trial name
- NCT03037580
- Testing
- Oral treprostinil
- Where
- 82 sites in United States
- Volunteers
- 84 people
- Sponsor
- United Therapeutics
Acute Heart Failure
An Observational Study of the Functional Capacity of Heart Failure
This is an observational study of the functional capacity of patients with Heart failure with Reduced Ejection Fraction (HFrEF) who are admitted to the hospital for routine medical treatment.
- Trial name
- NCT02350114
- Testing
- 6 Minute Walk Test
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Disease, Chronic Obstructive
Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation
The purpose of this study is to evaluate effects of inspired gas mixtures on the distance walked by patients with severe Chronic Obstructive Pulmonary Disease (COPD) during a Six-Minute Walk test.
- Trial name
- rehabilitate (NCT01355809)
- Testing
- Inhalation gas, Inhalation Nitrogen/Oxygen, Inhalation Helium/Oxygen
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Air Liquide SA
Pulmonary Arterial Hypertension
Combination Therapy in Pulmonary Arterial Hypertension
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary…
- Trial name
- COMPASS 3 (NCT00433329)
- Testing
- Bosentan, Sildenafil
- Volunteers
- 100 people
- Sponsor
- Actelion
Pulmonary Hypertension, Interstitial Lung Disease
A Study of Mosliciguat in PH-ILD
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
- Trial name
- PHocus (NCT06635850)
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 85 sites in United States, Argentina and 18 more
- Volunteers
- 135 people
- Sponsor
- Pulmovant, Inc.